A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of RBS2418 Plus Best Supportive Care (BSC) in Subjects with Advanced, Metastatic, and Progressive Colorectal Cancer
Latest Information Update: 21 Feb 2025
At a glance
- Drugs RBS 2418 (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms VISTA-1
- Sponsors Riboscience
Most Recent Events
- 21 Feb 2025 New trial record